openFDA
Cure8 regulatory brief
Dexamethasone FDA label update (2026-07-07)
Medications
Corticosteroids
Steroids
Regulatory Update
Adult patients
Clinicians
Patients On Biologics
Inflammatory bowel disease
Why This Matters
This is the FDA DailyMed label for dexamethasone, which lists gastrointestinal uses including short-term use in ulcerative colitis and regional enteritis (Crohn's disease). Patients with IBD may be prescribed dexamethasone for acute control of severe inflammation or related complications.
Who Should Pay Attention
Adult patients with IBD (Crohn's disease or ulcerative colitis), clinicians prescribing systemic steroids, pharmacists, and caregivers of patients who may receive corticosteroids.
Study Snapshot
Story typeRegulatory
Evidence typeRegulatory update
Study statusHuman prescription drug
Source depthRegulatory record
What To Know
This record lists approved indications, dosing ranges, and general administration guidance for oral and parenteral dexamethasone, including pediatric dosing and typical short-course regimens for acute allergic or cerebral edema situations.
The label emphasizes individualized dosing, gradual tapering after long-term therapy, and equivalent-dose comparisons with other corticosteroids such as prednisone and methylprednisolone. The entry is a regulatory drug-label document (DailyMed/NLM) and reflects official prescribing information rather than new clinical research.
It is intended to inform clinicians and patients about approved uses and recommended dosing, not to provide personalized medical advice.
Practical note: If your care team is considering systemic steroids for an IBD flare, they'll weigh steroid benefits and known risks and plan dosing and tapering; refer to your prescriber or pharmacist for how this label applies to your situation.
Keep In Mind
This is an official drug-label (regulatory-record) listing indications, dosing guidance, and safety precautions. It is not new clinical-trial evidence; dosing and use should be interpreted by a clinician familiar with the patient's history. The extraction is from the DailyMed label (U.S. prescribing information).
Source Details
Review the original publication for the complete reporting, methods, and context.
Regulatory update
Evidence type derived from source or registry metadata.
PublicationopenFDA
Study typeDrug Label Update
Indexed viaopenFDA
Source typeRegulatory record
PublishedJul 7, 2026, 12:00 AM
Content availableRegulatory record
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Understanding role of microbiota in Crohn's disease, ulcerative colitis
The article explains how gut bacteria may contribute to IBD and summarizes common tests and treatments people are likely to encounter. It highlights emerging microbial therapies (probiotics and FMT) that some patients...
Large Vessel Vasculitis in IBD Linked to Younger Onset, Distinct Clinical Features
This study suggests LVV can occur in people with IBD at younger ages and with distinct vascular findings, and it may arise even when gut disease is in remission. That matters for awareness, diagnosis, and coordination...
‘Getting closer’: Genetic risk scores may help predict inflammatory bowel disease severity
This research suggests genetic risk scores could help identify people with IBD who are more likely to have severe disease, which might eventually inform earlier monitoring or treatment decisions. It’s a step toward more...